Abstract Fragile X syndrome (FXS) is one of several clinical disorders associated with mutations in the X-linked Fragile X Mental Retardation-1 (FMR1) gene. With evolving knowledge about the phenotypic consequences of FMR1 transcription and translation, sharp clinical distinctions between pre-and full mutations have become more fluid. The complexity of the issues surrounding genetic testing and management of FMR1-associated disorders has increased; and several aspects of genetic counseling for FMR1 mutations remain challenging, including risk assessment for intermediate alleles and the widely variable clinical prognosis for females with full mutations. FMR1 mutation testing is increasingly being offered to women without known risk factors, and newborn screening for FXS is underway in research-based pilot studies. Each diagnosis of an FMR1 mutation has farreaching clinical and reproductive implications for the extended family. The interest in large-scale population screening is likely to increase due to patient demand and awareness, and as targeted pharmaceutical treatments for FXS become available over the next decade. Given these developments and the likelihood of more widespread screening, genetic counselors across a variety of healthcare settings will increasingly be called upon to address complex diagnostic, psychosocial, and management issues related to FMR1 gene mutations. The following guidelines are intended to assist genetic counselors in providing accurate risk assessment and appropriate educational and supportive counseling for individuals with positive test results and families affected by FMR1-associated disorders.
Introduction
The FMR1 gene is characterized by a repetitive trinucleotide sequence that includes 6 to 44 CGG repeats in the normal allele. Premutation alleles result from an unstable trinucleotide expansion in the range of 55 to 200 CGG repeats and are unmethylated. During oogenesis in females and during post-zygotic mitosis in males or females, premutations may undergo further size expansions to become methylated full mutations with more than 200 CGG repeats; hypermethylation leads to transcriptional silencing of Fragile X Mental Retardation Protein (FMRP). Mosaicism occurs related to both repeat number (size mosaics) and less commonly, degree of hypermethylation (methylation mosaics) (Rousseau et al. 1994) ). The chance of FMR1 expansion in females is correlated with repeat size (Table 1) and may be increased in women with a family history of FXS as compared to those without (Nolin et al. 2011) . Expansion is influenced by the absence of normally interspersed AGG triplets and the length of total and uninterrupted CGG repeats at the 3′ end of the repeated CGG region (Yrigollen, et al. 2012) . Recently developed PCR assays ) should provide definitive data on which of these factors more accurately estimates the risk for instability as compared to repeat size alone. Research is also needed to determine the impact, if any, of routinely incorporating AGG testing results into genetic counseling practice for FMR1 mutations.
Intermediate or gray zone alleles overlap the junction between the normal and premutation ranges and are defined by the American College of Medical Genetics (ACMG) as having between 45 and 54 CGG repeats (Sherman et al. 2005) . These intermediate size alleles may or may not be unstable. An unstable intermediate allele can expand to a premutation in offspring and to a full mutation in subsequent generations. It should be noted that expansions and contractions of CGG repeat number can occur in alleles of any size, even those within the normal range. The vast majority of intermediate alleles are stable (Levesque et al. 2009) , and most often an expansion or contraction is minimal (from 1 to 5 CGG repeats). There have been a few reports of alleles in the 50 to 54 repeat range with expansions or contractions of >10 CGG repeats (Nolin et al. 2003) . Expansion to a full mutation in one generation from a maternal allele with fewer than 56 repeats has not been reported.
Prevalence
Population studies suggest a prevalence of FXS in 1 in 4,000 males and 1 in 8,000 females (Crawford et al. 2001) . Mutation prevalence studies vary in terms of repeat cutoffs and sample sizes, and there is some evidence for ethnic and racial variability. Premutation frequencies in females range from 1/151 -1/259 (North America) to 1/113 (Israel) (Rousseau et al. 1995; Toledano-Alhadef et al. 2001; Seltzer et al. 2012) , while the rate in males ranges from 1/468 to 1/813 (Dombrowski et al. 2002; Seltzer et al. 2012) . Intermediate alleles are observed in approximately 1/35 to 1/57 females (Cronister et al. 2008; Seltzer et al. 2012) and are often coincidentally identified on general population prenatal screening, during the diagnostic work-up of a child with developmental delay or autism, or as part of an infertility evaluation. Population-based screening studies will provide valuable data which will more accurately define the prevalence of all FMR1 alleles.
Laboratory Testing
The FMR1 gene can be analyzed using a combination of polymerase chain reaction (PCR) and Southern blot analysis. Testing is 99 % sensitive, missing only rare individuals who have FXS due to point mutations or deletions located outside the CGG repeat region. ACMG's Standards and Guidelines for Clinical Genetics Laboratories (Spector and Kronquist 2006) details testing methodology and defines the normal and mutation categories and corresponding CGG repeat ranges. Alternative methods for determining the length of uninterrupted CGGs Nolin et al. 2011) , and assessing full mutation Chen et al. 2010 ) and methylation status (Chen et al. 2011 ) without performing Southern blot are under development and available through select laboratories, as are other novel PCR methodologies (Lyon et al. 2010) . Although FMR1 analysis is highly accurate, laboratories typically state that the reported allele size may vary by ±1 to 4 CGG repeats for alleles less than~120 CGG repeats. For larger alleles, the accuracy is ±10 %. This generally has no implications for the patient, although occasionally, additional family studies may aid interpretation. As always, when counseling patients, the session should be based on the specific results reported and include a discussion of the risk for expansion based on the laboratory's interpretation of those results.
Clinical Presentation
A wide range of clinical effects is associated with expanded FMR1 alleles. Hypermethylated full mutations fail to (Bear et al. 2004) . By contrast, FMR1 premutations produce relatively normal levels of FMRP but are associated with elevated mRNA. Premutation disorders such as Fragile X-associated tremor ataxia syndrome (FXTAS) and Fragile X-associated primary ovarian insufficiency (FXPOI) are thought to be related to mRNA toxicity which results in sequestration of proteins and mitochondrial dysfunction (Garcia-Arocena and Hagerman 2010). Overlap exists among the FMRP levels, mRNA levels, and clinical phenotypes associated with premutation and full mutation expansion ranges, and these should be viewed as a continuum rather than distinct allele types (Hagerman and Hagerman 2004) (Table 2 ).
Full Mutations
In males and females, full mutations are associated with FXS, a spectrum of clinical effects that includes physical, cognitive, and behavioral aspects (Table 3) . Variability in the clinical phenotype is related to methylation status, mosaicism, and X-inactivation. Most males with FXS function within the mild to severe range of intellectual disability and exhibit a variety of maladaptive behaviors which significantly overlap behavioral criteria for autism spectrum disorders (Hagerman 2002) . Females with full mutations show greater clinical variability than males (De Vries et al. 1996) . Half manifest symptoms of FXS, although intellectual impairment is often milder.
Emotional and psychiatric problems are common (Keysor and Mazzocco 2002) , even among intellectually normal females with full mutations. Some females appear to be completely unaffected by the full mutation, and others exhibit subtle neurobehavioral features, such as difficulty with math or excessive shyness, without other major phenotypic effects (Cronister et al. 1991) .
Premutations
Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
Characterized by progressive neurological, cognitive, and psychiatric features, FXTAS is a neurodegenerative condition associated with FMR1 premutations (Hagerman et al. 2001) , with typical onset after age 50. Neurologically, the disorder is associated with intention tremor, cerebellar ataxia, peripheral neuropathy, atypical parkinsonism, and dementia. Cognitive features include declines in intellect, short-term memory, and executive functioning. Psychiatric symptoms may be present, such as personality or mood changes, increased irritability, and impulsive behavior. The diagnosis of FXTAS is based on clinical findings in older adults confirmed to have FMR1 alleles in the premutation range. Hyperintensities of the middle cerebellar peduncles are often seen on brain MRI in patients with FXTAS and may be a useful diagnostic sign (Hagerman et al. 2001) . Approximately 46 % of males and as many as 17 % of females with premutations develop neurodegenerative symptoms of FXTAS after age 50 (Rodriguez-Revenga et al. 2009 ); some individuals may experience neurological symptoms that do not meet full clinical criteria for the diagnosis of FXTAS (Table 4) . (Sherman 2000) and is correlated in a non-linear association with CGG repeat number. The risk for FXPOI increases with CGG repeat numbers from 55 to about 95, plateaus at about 100, and then drops off as premutations approach 200 repeats (Allen et al. 2007 ). The prevalence of FMR1 premutations is approximately 2 to 7 % in women who have sporadic ovarian insufficiency and 10 to 15 % in those with a family history of ovarian insufficiency (Wittenberger et al. 2007 ). The risk of developing FXPOI is not increased for women with FMR1 full mutations, nor is there convincing evidence for a significant increase in FXPOI among women who have intermediate FMR1 alleles (Bennett et al. 2010 ).
Other Premutation-Associated Issues
Research has shown the vast majority of males and females with FMR1 premutations to have normal intellectual functioning. There have been a handful of case reports of children with premutations who have learning and/or behavioral disabilities (Aziz et al. 2003) , in some cases with documented decreases in FMRP, illustrating the overlap in clinical features between repeat ranges (Loesch et al. 2009a ). An increased incidence of hypertension, thyroid disorders, fibromyalgia, tremor, and neuropathy has been reported among adult women with premutation alleles (Coffey et al. 2008) . Additionally there is a higher than expected prevalence of mental health issues in these women which appear to be independent of (although likely exacerbated by) the stress of raising a child with FXS (Hagerman and Hagerman 2004; Lachiewicz et al. 2010) . Hunter et al. (2010) found that women with FXPOI reported higher rates of thyroid problems, depression, and anxiety, suggesting a possible link to ovarian dysfunction. There is also evidence that anxiety may be among the clinical symptoms related to mRNA toxicity in FXTAS or FXPOI. Hessl et al. (2005) reported elevated levels of mRNA in individuals with premutations who had psychiatric symptoms; and MRI changes were found to correlate with anxiety in women with FMR1 premutations, even in those without a clinical diagnosis of FXTAS (Adams et al. 2010 (Loesch et al. 2009b) , primary ovarian insufficiency (Bodega et al. 2006) , and autism and cognitive disabilities (Aziz et al. 2003; Loesch et al. 2009a ). However, these findings have not consistently been supported Clinical features are highly variable and tend to be more pronounced in males than females; macroorchidism and distinctive facial characteristics may not become apparent until after puberty Jacquemont et al. 2003 and Hagerman and Hagerman 2004 by other studies (Ennis et al. 2006; Bennett et al. 2010 ) and can be difficult to interpret due to inconsistencies in the way researchers have defined the intermediate range. Additional research is needed to clarify the clinical relevance of intermediate alleles.
Population Screening
The ACMG's Policy Statement on FXS (Sherman et al. 2005 ) describes individuals for whom FMR1 mutation testing should be considered. Likewise, the American College of Obstetrics and Gynecology (ACOG) has published a committee opinion on premutation screening for FXS (ACOG 2010) ( Table 5 ). Although currently not endorsed by ACMG, FMR1 mutation testing is increasingly being offered to women without known risk factors for FXS. ACOG is cautious about widespread population-based screening but recommends offering testing, along with genetic counseling, to women who request it, regardless of family history. General population studies of FMR1 testing in women have demonstrated its efficacy and cost effectiveness (Musci and Caughey 2005) . Voluntary screening for FMR1 mutations appears to be acceptable to women in the general population and to the parents of affected children (Bailey et al. 2003; Hill et al. 2010) . Genetic counseling and education are essential, and research on the psychological impact of positive fragile X results is needed before population-based screening is endorsed more broadly. Newborn screening for FXS is also under consideration, but further research is needed to determine its acceptability and efficacy (Hill et al. 2010 ).
Prenatal and Pre-implantation Genetic Diagnosis
Prenatal detection of FMR1 mutations by amniocentesis and chorionic villus sampling (CVS) is accurate and reliable (Nolin et al. 2011) . Although FMR1 methylation is incomplete in placental tissue at 10 to 12 weeks gestation, methylation patterns can usually be interpreted and used to distinguish between pre-and full mutations. On rare occasions, follow-up amniocentesis may be needed to confirm the presence or absence of an unmethylated full mutation. A variety of other preand post-conception options, including pre-implantation genetic diagnosis (PGD), adoption, and gamete donation, is available to couples at risk for having children with FMR1 gene mutations. PGD for FXS using PCR and linked polymorphic markers can be hampered by difficulties with oocyte retrieval, amplification of the CGG repeat, and the ability to distinguish FMR1 alleles (Tsafrir et al. 2010 ).
Management of FXS
Children with FXS benefit from a comprehensive developmental and educational evaluation to identify appropriate interventions. A team approach which includes parental concerns and integrates occupational, physical, and speech therapies within a special education program is recommended (Braden 1996) . A combination of environmental supports and psychotropic medications can be used to treat FXS behavioral symptoms (Hagerman et al. 2009 ). Research suggests that epigenetic polymorphisms related to drug metabolism may help predict responses to specific medications in people with FXS (Hagerman et al. 2009 ).
Because its physiological mechanism is well-elucidated and has been replicated in animal models, FXS shows particular promise for the development of targeted pharmaceuticals aimed at addressing the underlying biochemical basis for the disorder (Hagerman et al. 2009 ). Targeted treatment approaches focus on regulation of the mGluR pathway through drugs that mimic the effect of FMRP. Studies of mGluR antagonists in FXS knockout mice have shown a positive effect on seizures, behavior, and cognition (Ogren and Lombroso 2008) . Some of these medications are currently in human clinical trials and expected to enter the drug market within the next few years. The development of pharmaceuticals that target dysregulation of the mGluR pathway offers hope to families affected by FXS; these drugs may also prove effective for the broader treatment of autism unrelated to FXS (Hagerman et al. 2009 ). Table 7 . Given the subjective nature of behavioral and cognitive symptoms, psychiatric and educational records should be obtained whenever possible to confirm a reported history of developmental issues. & The diagnosis of FMR1-associated disorders can have farreaching genetic and emotional implications for extended family members. When an FMR1 mutation is identified in a family, genetic counselors should assist patients in developing strategies to inform relatives. & Parents should be encouraged to explore open and meaningful discussion with their children about FMR1-associated disorders and genetic risk. Genetic counselors should work toward helping parents develop a positive, resilient communication style which may aid in the long-term adaptation of children to FMR1-related risk. & Psychiatric issues, as well as cognitive decline, are common among patients with FXTAS. They may experience confusion and emotional reactions to learning the genetic nature of their condition and its implications for their children and other relatives. With the patient's consent, it may be important to involve other family members and caregivers in these discussions so that genetic and management information is accurately communicated. 
Conclusion
When FXS was originally described as a rare, X-linked pediatric disorder (Lubs 1969) , genetics professionals could not have anticipated the layers of molecular and phenotypic complexity that would eventually be revealed about FMR1 and its associated disorders. Research into FMR1-related genetic and clinical phenotypes is actively being pursued on many fronts, including: molecular features that influence gene instability; epigenetic factors that contribute to clinical variability; targeted pharmaceuticals; and the emotional and societal impact of population screening. As our understanding of these issues evolves, genetic counselors will need to regularly update their knowledge of FMR1-associated disorders and adjust their counseling approaches to address the far-reaching impact of these conditions on patients and families.
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